Nektar Therapeutics

1.16 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nektar Therapeutics stock is down -29.27% since 30 days ago. The next earnings date is Aug 6, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.71% of the previous 30 June’s closed higher than May. In the last 1 Unusual Options Trades, there were 1 CALL.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
10 May 17:26 17 May, 2024 1.00 CALL 320 6356

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus